# Elevate Holistics Launches At-Home Ketamine Telehealth: What Care Teams Should Note

> A GlobeNewswire release carried by The Manila Times describes an online, low-dose ketamine service with virtual evaluations, clinician onboarding and monthly check-ins. Here is what it says and leaves out.

SmartMeet Desk · 2026-10-06 · https://blog.smartmeet.myipms.app/elevate-holistics-launches-at-home-ketamine-telehealth-what-care-teams-should-no

On October 5, 2026, The Manila Times carried a GlobeNewswire press release in which Elevate Holistics, a self-described telehealth provider, announced an online platform for at-home, low-dose ketamine treatment [1]. The service, Elevate Ketamine, combines virtual provider evaluations, behavioral health support, ongoing monitoring and home delivery of medication through licensed pharmacy services [1]. It currently serves eligible patients in Arizona, Florida, Missouri, Oklahoma and Washington, with expansion to other states planned [1].

The item is a company announcement rather than independent reporting, and its distribution notice states that the distributor and its partners do not endorse the information or vouch for its accuracy, completeness or reliability [1].

## How the care pathway is built

The release describes a pathway that patients complete virtually [1]:

1. An online health and symptom screening [1].
2. A telehealth evaluation in which a licensed provider reviews medical history, current medications and symptoms; certain medical and psychiatric conditions may make a patient ineligible [1].
3. A one-hour onboarding session with a licensed behavioral health clinician before medication is dispensed, covering preparation such as a playlist, journaling, breathwork and the home setting [1].
4. Dispensing by a licensed compounding pharmacy, which ships troches, the dosage form the company uses, to the patient's home [1].
5. Monthly check-ins for continued provider oversight and review of treatment plans, which the release also describes as a chance to review progress and address safety concerns [1].

The schedule runs to approximately 16 doses per month with built-in breaks between sessions, which the company frames as structured intervals paired with behavioral health practices [1]. The chief executive, identified as Aspen, said: "Ketamine is a tool, not a replacement for active participation in your own care" [1]. The company also states that individual responses vary [1].

## Why it matters for clinicians and care teams

The release states that ketamine was approved by the U.S. Food and Drug Administration as an anesthetic in 1970 and that prescribing it for mental health conditions is off-label, that is, outside the anesthetic use for which it was approved [1]. The model places that prescribing inside a chain of scheduled clinical contacts: screening, a provider evaluation, a clinician-led onboarding hour and monthly reviews [1]. For practitioners whose patients or clients ask about such services, the release sets out what this provider says its pathway includes [1].

The company's background is in medical cannabis access, and it states, without independent verification in the release, that it has helped more than 100,000 patients obtain legal access to medical cards [1]. It says it entered ketamine care after seeing interest from people whose earlier approaches had not given them the results they wanted [1].

## The evidence the release cites

The release refers to a 2024 randomized, placebo-controlled phase 2 trial in Nature Medicine that tested extended-release oral ketamine tablets in treatment-resistant depression and reported a 72.7% response rate in the relevant treatment group [1]. The release gives no sample size, placebo-group result, definition of response or confidence interval [1]. That trial studied extended-release tablets, whereas the platform dispenses compounded troches on its own dosing schedule, and the release presents no outcome data for that regimen [1].

## What to watch next

- Which additional states the company enters, since it names expansion plans without specifics [1].
- How the check-ins handle safety concerns, which the release mentions without describing a protocol [1].
- Which medical and psychiatric conditions lead to exclusion, as the release does not list them [1].
- Whether the company publishes outcomes for its spaced-dosing model, for which the release offers none [1].

## Limitations

This piece rests on a single source, a company press release republished by a news site, so every description of the service reflects the company's own account [1]. The trial is reported only as the release summarizes it, without the design details needed to judge its strength or its relevance to this service [1].

## References

1. manilatimes.net. Elevate Holistics Launches Telehealth Platform for At-Home, Low-Dose Ketamine Care. Accessed October 5, 2026. https://www.manilatimes.net/2026/10/05/tmt-newswire/globenewswire/elevate-holistics-launches-telehealth-platform-for-at-home-low-dose-ketamine-care/2438696